VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2 - Wikidata - wikimedia - TriplyDB

VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2

VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2

http://www.wikidata.org/entity/Q57904509

about

Intertwined regulation of angiogenesis and immunity by myeloid cells Control of the immune response by pro-angiogenic factors Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment The role of immune checkpoint inhibition in the treatment of ovarian cancer Canonical and noncanonical Wnt proteins program dendritic cell responses for tolerance Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)CD47 signaling regulates the immunosuppressive activity of VEGF in T cells.VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Lymphangiogenesis and cancer VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2 Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro Cancer prevention and therapy through the modulation of the tumor microenvironment.Mycobacterium tuberculosis exploits the formation of new blood vessels for its dissemination.The angiogenic activity of ascites in the course of ovarian cancer as a marker of disease progression Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation Neuropilin 1: function and therapeutic potential in cancer.Immunological effects of chemotherapy and radiotherapy against brain tumors.The Unique Molecular and Cellular Microenvironment of Ovarian Cancer Barriers to Radiation-Induced In Situ Tumor Vaccination.Angiogenesis inhibitors in tackling recurrent glioblastoma.Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity.The role and significance of VEGFR2+ regulatory T cells in tumor immunity VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.Antitumor immunity induced by VE-cadherin modified DC vaccine.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway.Targeting VEGF/VEGFR to Modulate Antitumor Immunity.[Impact of VEGF-A in exhaustion of intratumoral T cells].Autoantigen-Harboring Apoptotic Cells Hijack the Coinhibitory Pathway of T Cell Activation Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications Exploring immuno-regulatory mechanisms in the tumor microenvironment: Model and design of protocols for cancer remission

P2860

Q26830418-FDD0C095-AA36-4C9D-92D8-2DE16177192F Q27004733-903E5ABE-41FA-49E9-923E-D68A23A72FA6 Q28073057-30D854D8-2084-4325-BF21-5FCBDE7A3FC3 Q28077924-D3F8501A-86EE-448B-8A20-FC7577EC2E63 Q28510103-01032D9A-3B87-4A16-A3C6-6C6EC7BA7200 Q30412106-C5BFB03F-4661-41DA-9D56-DAA5AE0E5E9D Q34289358-F5584999-C8DB-40DD-92D5-0B44D4B0DA0E Q35064894-59BEF7DE-A4A6-4990-88C1-4577B8DA3AB7 Q35954103-09758717-93BB-45E0-B17F-3230A0F83A48 Q36137692-B2425D93-D9FD-4547-B79D-ACC8E8B23FA6 Q36419140-697F403B-5285-4490-B76B-E43C5B4B90B9 Q36842192-16057DD0-6D80-40F5-9CE6-62469F86DC69 Q37058267-16C8792B-3706-467A-BAC7-C279182EEC62 Q37247778-34E945F3-8CB6-4271-8898-8CC877F911D2 Q37586773-A6A6B770-736A-4442-85BB-44DCCD161C57 Q38008362-4B82396B-1F0A-4A98-AE4E-88CF899ECCF9 Q38165001-2D074A37-175A-422A-8930-00D01F0DDD00 Q38947116-EB664CD1-6AB0-4062-9BA0-4A1523F9C988 Q39169603-755AA356-7F86-4EFA-9853-7801EB8081A7 Q39203685-6DA7846C-81DD-4AED-9999-0B3DE7BCB5A0 Q39259089-502BC2B6-F9A9-4ACB-B408-99B221417AD9 Q40088326-01BD2861-6DC4-4C87-B5CB-2EA4D2B7884F Q41499942-2D3FAF8D-8BAE-4FFD-A37C-584E7A156B6D Q41738853-1BCB9A7F-7842-4C0F-AFC2-FABDB447DC0E Q42366549-4132202F-049B-4E48-A09E-CBC6DA016E5E Q47285613-94716DBA-5CFF-4C4E-AB58-43D6C2634F75 Q48099660-91403F69-597A-49F7-89E6-D948E27E938C Q55008337-6B7D2D3C-AD08-461A-98F9-96965BFFD66C Q55056908-8D1F9DFE-7B52-415F-897A-C224085DD4BF Q57176332-7397C8A2-437D-44D5-A660-6C4AE511305A Q58760425-4FBA90DD-D875-49CE-AB0E-C532BB853B89 Q58763679-A47D4FE4-DA4B-432D-BA35-9895777D111F

P2860

VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2

http://www.wikidata.org/entity/Q57904509

description

im Mai 2011 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в травні 2011

@uk

name

VEGF directly suppresses activ ...... duals via VEGF receptor Type 2

@en

VEGF directly suppresses activ ...... duals via VEGF receptor Type 2

@nl

type

label

VEGF directly suppresses activ ...... duals via VEGF receptor Type 2

@en

VEGF directly suppresses activ ...... duals via VEGF receptor Type 2

@nl

prefLabel

VEGF directly suppresses activ ...... duals via VEGF receptor Type 2

@en

VEGF directly suppresses activ ...... duals via VEGF receptor Type 2

@nl

P1433

Q57904509-F329F16A-65B7-4CF9-BD9A-41E74DCB9698

P1476

Q57904509-507E47E7-9FDF-48C1-ADA0-B2EF6C0D63A7

P2093

Q57904509-074A6615-2D59-4090-9608-EAB1A51EE8AA

Q57904509-657B2D17-1FE3-47F6-BE91-010AA11269F6

Q57904509-71121B17-B19E-4A74-96B9-4B4B7F30EBD9

Q57904509-78F5B156-A087-4B26-BF8C-4B2F378475CA

Q57904509-8CBBEF19-175E-4B4A-9DCE-3621D50EB3F5

Q57904509-9C1B0A23-E12A-4188-8EA1-7BD6A11496A3

Q57904509-9C6BFB6B-B1BE-42DD-A3B7-7A1868B00AB5

Q57904509-A57D4F62-88C8-423E-92C4-D43D72645356

Q57904509-B0D1359B-C6A0-4B56-BA77-E3E62837C268

Q57904509-DE2626C6-FA32-4961-8368-6BC40D9AFED8

P2860

Q57904509-1623A3A4-76DB-41B8-85DA-F5CED0FA1727

Q57904509-2395708A-8838-4DC6-B1D4-0DF13278358B

Q57904509-44AA6C99-CC83-4347-94ED-1AA1D82DC079

Q57904509-45FB77CF-69DD-43D7-B9F9-3C8B6CC21B88

Q57904509-49B2CD23-F9C7-4250-9FFE-2E1570CD8AEA

Q57904509-61ED19E0-0365-45B2-864C-069309267E0A

Q57904509-7C11DC7A-B466-4954-9C19-1D3A4FA5E6BF

Q57904509-82C304C0-43F8-4EF3-8CB4-AD63C5099BE8

Q57904509-88D62F04-A9D6-4193-96E7-9F5558DF94AE

Q57904509-8BCF71BB-19A1-4E01-A409-C5D6AE96E4C0

P304

Q57904509-C9B05DFB-0499-48E9-B846-D833356B8F7D

P31

Q57904509-5E9A2708-53A3-46B7-8C84-FD240002597D

P356

Q57904509-1C591206-B925-4A5D-B1DC-7387CD5D369D

P433

Q57904509-60847089-BE42-4119-8CE5-FC69F569893D

P478

Q57904509-D00FEE46-DE5C-4E35-BF6E-C978F5F86FF7

P50

Q57904509-BE804453-A32F-4521-A1F4-53458029AA55

P577

Q57904509-83226705-8C50-48C7-9542-73E0FB5780B8

P698

Q57904509-44C04325-0DFA-4EAC-A5B3-5DF3BA2D1C64

P921

Q57904509-9E239E04-30C9-487C-B52C-26B3761F7731

Q57904509-A9364A09-3299-48BD-8449-2171059034FD

P356

P1433

International Journal of Cancer

P1476

VEGF directly suppresses activ ...... duals via VEGF receptor Type 2

@en

P2093

Alexandros Rodolakis

http://www.w3.org/2001/XMLSchema#string

Apostolos C. Ziogas

http://www.w3.org/2001/XMLSchema#string

Aristidis Antsaklis

http://www.w3.org/2001/XMLSchema#string

Aristotle Bamias

http://www.w3.org/2001/XMLSchema#string

Dimitrios Haidopoulos

http://www.w3.org/2001/XMLSchema#string

Ekaterini Politi

http://www.w3.org/2001/XMLSchema#string

Evangelos Terpos

http://www.w3.org/2001/XMLSchema#string

George Vlahos

http://www.w3.org/2001/XMLSchema#string

Marinos Tsiatas

http://www.w3.org/2001/XMLSchema#string

Nikolaos Thomakos

http://www.w3.org/2001/XMLSchema#string

P2860

Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Tumorigenesis and the angiogenic switch

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

Vascular endothelial growth factor: basic science and clinical progress.

Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo.

Angiogenic inhibitors: a new therapeutic strategy in oncology.

Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production.

EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2.

Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.

P304

857-864

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.26094

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

P577

2011-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21445972

http://www.w3.org/2001/XMLSchema#string

P921

cancer research